Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est

Benzinga Newsdesk www.benzinga.com Negative 61.7%

Neg 61.7% Neu 0% Pos 0%

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.